Multisystem inflammatory syndrome in adults: Characteristics, treatment, and outcomes

Chih Cheng Lai, Chi Kuei Hsu, Shun Chung Hsueh, Muh Yong Yen, Wen Chien Ko, Po Ren Hsueh

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)

Abstract

Following the rapidly increasing number of multisystem inflammatory syndromes in children (MIS-C), a similar clinical scenario has been observed in adult patients. Although its prevalence is low and probably related to underdiagnosis, its development can be associated with high mortality. Multisystem inflammatory syndrome in adults (MIS-A) can develop following both asymptomatic and symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and in previously healthy people. Like MIS-C, MIS-A is a multisystem disease that can involve the cardiovascular, respiratory, gastrointestinal, dermatologic, hematologic, and neurologic systems. In addition to the clinical manifestations, the diagnosis of MIS-A requires laboratory evidence of inflammation and SARS-CoV-2 infection. The appropriate treatment for MIS-A remains unclear; anti-inflammatory agents, including intravenous immunoglobulin and corticosteroids, are commonly used. However, there are still many unknowns regarding MIS-A. Further studies are needed to determine the true prevalence, pathogenesis, and effective treatment for MIS-A.

Original languageEnglish
Article numbere28426
JournalJournal of Medical Virology
Volume95
Issue number2
DOIs
Publication statusPublished - 2023 Feb

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Virology

Fingerprint

Dive into the research topics of 'Multisystem inflammatory syndrome in adults: Characteristics, treatment, and outcomes'. Together they form a unique fingerprint.

Cite this